GlobeNewsWire
23 Sept 2026, 11:47 UTC · 3h ago
Verdict
Headline takes no side. We score BBIO +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Acoramidis showed a 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) compared to tafamidis (p=0.046).
Newtoday announced results published in Cardiology and Therapy
So whatSuperiority over the market leader tafamidis likely increases market share capture and elevates peak sales estimates for Attruby.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Acoramidis was associated with a 43% reduction in the risk of diuretic intensification versus tafamidis (p=0.021).
Newtoday announced results published in Cardiology and Therapy
So whatAs diuretic intensification is an early marker, this supports a strategy to switch patients from existing therapies within the next 12 months.
More positive than 92% of claims this week
An independent real-world study using electronic health records data comparing acoramidis to tafamidis is expected at an upcoming 2026 medical meeting.
Newexpected to be released at an upcoming 2026 medical meeting
So whatPositive corroboration from a second dataset would further solidify the competitive moat before the end of FY2026.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
The company's drug acoramidis demonstrated statistically significant superiority over a competitor in reducing clinical worsening events in a peer-reviewed study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
−2.0%
Price is moving against the score
$67.85 vs $69.23 close before publication (Sep 22) · not market-adjusted
BBIO chart →
